Citadel Advisors
OMIC

Citadel Advisors’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Citadel Advisors’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-490
Closed -$12.2K – 15367
2023
Q2 		$12.2K Buy
490
+477
+3,669% +$14K ﹤0.01% 13091
2023
Q1 		$484 Buy
13
+10
+333% +$613 ﹤0.01% 14488
2022
Q4 		$201 Buy
+3
New +$201 ﹤0.01% 14729

Other funds holding OMIC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
QM
QVIDTVM Management The Woodlands, Texas $81.4M AUM 2.94% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Citadel Advisors's OMIC Position: Q2 2024 in Review

Citadel Advisors sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q2 2024, closing a stake of 3,897 shares — an estimated $60.1K sold.

Citadel Advisors first reported a position in OMIC in Q2 2021 and held it in 12 quarters. The position peaked at $7.01M in Q2 2021. 24 funds tracked by Wall St. Rank hold OMIC as of Q2 2024.

  • Citadel Advisors reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 3,897 Singular Genomics Systems, Inc. Common Stock shares in Q2 2024, an estimated $60.1K.
  • Citadel Advisors first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
  • Citadel Advisors's Singular Genomics Systems, Inc. Common Stock position peaked at $7.01M in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.